Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALYCANTE: Axi-Cel as 2nd Line Therapy in Relapsed/Refractory Aggressive B-NHL
NCT04531046Phase 2Active, not recruiting
- Sponsor
- LYSARC
- Start
- Mar 2021
- Primary completion
- Apr 2022
- Modality
- CAR-T Cells
- Countries
- 2
01
Overview
A Phase 2 trial of axicabtagene ciloleucel in B-cell non-Hodgkin lymphoma, sponsored by LYSARC. Started Mar 2021; status: active, not recruiting.
02
Drugs
axicabtagene ciloleucel
03
Conditions
B-cell non-Hodgkin lymphoma
Beyond the preview
Go deeper on NCT04531046.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04531046.